Physician profile
Matthew Rider
NPI 1699909481
$6,003.23
in general payments reported to CMS, 2019-2025
46 companies · $610 in 2025
The $610 reported for 2025 was more than what 83% of Brain Injury Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $869 · 2021: $1,313 · 2022: $916 · 2023: $794 · 2024: $631 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,035.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $1,035.05 | 2019-2025 | Dysport |
| Abbvie INC. | $590.86 | 2022-2025 | |
| Radius Health, INC. | $486.42 | 2019-2025 | Tymlos |
| Avanir Pharmaceuticals, INC. | $414.34 | 2019-2022 | |
| Amgen INC. | $368.52 | 2019-2025 | Evenity, Prolia, Prolia |
| Janssen Pharmaceuticals, INC | $318.57 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $317.57 | 2019-2025 | Xtampza, Belbuca |
| Pacira Therapeutics, INC. | $254.92 | 2019-2021 | |
| Allergan, INC. | $232.81 | 2019-2022 | |
| Pfizer INC. | $216.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $168.23 | 2021-2022 | |
| Tersera Therapeutics LLC | $142.77 | 2019-2025 | Prialt |
| Scilex Pharmaceuticals INC. | $122.19 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $114.69 | 2022-2025 | Xeomin |
| Otsuka America Pharmaceutical, INC. | $98.69 | 2023-2025 | Nuedexta |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Rider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.